Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC

NCT06195670 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

220

Enrollment

OTHER

Sponsor class

Conditions

CRC
Metastatic Colorectal Cancer
Metastatic Colorectal Adenocarcinoma

Interventions

DRUG: Experimental
DRUG: Active Comparator

Sponsor

Zhejiang Cancer Hospital